LUPIN-PROPRANOLOL LA CAPSULE (EXTENDED RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PROPRANOLOL HYDROCHLORIDE

제공처:

LUPIN PHARMA CANADA LIMITED

ATC 코드:

C07AA05

INN (International Name):

PROPRANOLOL

복용량:

60MG

약제 형태:

CAPSULE (EXTENDED RELEASE)

구성:

PROPRANOLOL HYDROCHLORIDE 60MG

관리 경로:

ORAL

패키지 단위:

15G/50G

처방전 유형:

Prescription

치료 영역:

BETA-ADRENERGIC BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0101831008; AHFS:

승인 상태:

APPROVED

승인 날짜:

2019-08-30

제품 특성 요약

_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LUPIN-PROPRANOLOL LA
Propranolol Hydrochloride Extended-Release Capsules
Extended-Release Capsules, 60 mg, 80 mg, 120 mg and 160 mg, Oral
USP
Beta-Adrenergic Receptor Blocking Agent
Lupin Pharma Canada Ltd.
1001 De Maisonneuve Est, Suite 304
Montréal, Quebec
H2L 4P9
Date of Initial Authorization:
AUG 28, 2019
Date of Revision:
JAN 14, 2022
Submission Control Number: 255723
_Page 2 of 30 _
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS...............................................................................................................
4
1.1
PEDIATRICS
.............................................................................................................
4
1.2
GERIATRICS
..............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
5
4.1
DOSING CONSIDERATIONS
........................................................................................
5
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.................................................... 5
4.4
ADMINISTRATION
......................................................................................................
6
4.5
MISSED DOSE
.........................................................................................................
6
5
OVERDOSAGE
.....